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Background: Despite their singular origin, monozygotic twin pairs often display discordance for complex disorders
including schizophrenia. It is a common (1%) and often familial disease with a discordance rate of ~50% in
monozygotic twins. This high discordance is often explained by the role of yet unknown environmental, random,
and epigenetic factors. The involvement of DNA methylation in this disease appears logical, but remains to be
established.
Methods: We have used blood DNA from two pairs of monozygotic twins discordant for schizophrenia and their
parents in order to assess genome-wide methylation using a NimbleGen Methylation Promoter Microarray.
Results: The genome-wide results show that differentially methylated regions (DMRs) exist between members
representing discordant monozygotic twins. Some DMRs are shared with parent(s) and others appear to be de
novo. We found twenty-seven genes affected by DMR changes that were shared in the affected member of two
discordant monozygotic pairs from unrelated families. Interestingly, the genes affected by pair specific DMRs
share specific networks. Specifically, this study has identified two networks; “cell death and survival” and a “cellular
movement and immune cell trafficking”. These two networks and the genes affected have been previously implicated
in the aetiology of schizophrenia.
Conclusions: The results are compatible with the suggestion that DNA methylation may contribute to the discordance
of monozygotic twins for schizophrenia. Also, this may be accomplished by the direct effect of gene specific
methylation changes on specific biological networks rather than individual genes. It supports the extensive genetic,
epigenetic and phenotypic heterogeneity implicated in schizophrenia.
Keywords: Monozygotic Twins, Schizophrenia, DNA Methylation, MeDIP, Methylation Array, Differentially Methylated
Regions (DMRs), snoRNA, Histone ClustersBackground
Monozygotic twins (MZ) have long been used to ascertain
the genetic and environmental contributions to complex
diseases, including schizophrenia [1]. Their unique aptness
lies in originating from the genetic content of a single zyg-
ote and sharing most in utero and postnatal environments.
Historically, the concordance and discordance for a dis-
ease between MZ twins has been attributed to unspecified
genetic and environmental factors, respectively [2]. The* Correspondence: ssingh@uwo.ca
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technologies has added a new supremacy to such studies.
Studies of this kind hold the potential to identify specific
mechanisms that contribute to the causation of disease
[3,4]. The first stage in these studies is to identify differ-
ences between monozygotic discordant (MZD) twins that
are expected to be genetically identical. The results during
the last few years have established that differences do exist
at the genetic [5,6] as well as epigenetic [7-9] levels. The
results argue that MZ twins are similar, but not identical
[6]. Also, the rare de novo mutations may take place dur-
ing developmental mitosis during ontogeny [6].ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Pedigrees of families included in the study. Shaded circles
represent the affected twins.
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twins have been reported as early as in newborns [10].
DNA methylation is reported to increase with age [11] and
accordingly, the methylation differences between monozy-
gotic twins increases with age [7]. Epigenetic differences
between MZ twins include features like X-inactivation,
genomic imprinting, or differential methylation of genes,
and may cause MZ twin pairs to diverge, leading to disease
discordance [3,12]. Studies of this kind have concluded that
no two individuals are alike; not even identical twins [6].
However, the genetic similarity between MZ twins is com-
parable to no other two individuals. In addition, identical
twins are matched for age, sex, maternal environment, and
population cohort effects - making them the best matched
control available [13]. Indeed, MZ twins provide a unique
backdrop to assess epigenetic states that are shared due to
inheritance or common environments, as well as differ-
ences that may be in response to individual specific expo-
sures or random events [7-9,14,15]. Such changes, if
operational, may allow monozygotic twins to develop dis-
cordance for almost any trait through reprogramming of
gene expression via epigenetic mechanisms which may in-
crease liability to disease [16]. This is particularly relevant
in neurodevelopmental disorders, especially schizophrenia,
and reports are now accumulating from twin studies to
support an epigenetic model of disease contribution. For
instance, it has been shown that the schizophrenic twin
from a pair of discordant twins is epigenetically more
similar to the affected concordant twins than to his own
unaffected co-twin at the DRD2 gene [17]. In addition,
methylation of genes in blood samples of twins discordant
for schizophrenia, including medication free patients,
shows hypermethylation and hypomethylation of several
genes [18,19].
Indeed, the molecular results accumulating on schizo-
phrenia are encouraging and include many recent re-
ports of associations between DNA methylation and
schizophrenia [12,20,21]. The evidence is also emerging
for lncRNAs as an important epigenetic contributor to
schizophrenia [22].
The research presented here identifies genes whose
methylation is altered in schizophrenia patients as
compared to their unaffected twin using genome-wide
assessment by Methylated DNA Immunoprecipitation
(MeDIP) on a Nimblegen Human DNA Methylation
Microarrays. It uses blood DNA from two sets of
monozygotic twin pairs discordant for schizophrenia
and their parents. The results identify DNA methyla-
tion differences between MZD twins in two families
discordant for schizophrenia. Also, the patients across
families share affected genes, and more importantly,
biological networks. The implications of the results
will require reports on an increasing number of MZD
twins but are particularly promising given that thegenes and networks identified are similar to accumu-
lating reports.
Methods
This study on monozygotic twins received ethics ap-
proval by the University of Western Ontario’s Commit-
tee on research involving human subjects. All subjects
provided written informed consent to participate in this
study. Further, they have agreed to the sharing of data
(genetic and clinical) in any publication. All of the pa-
tients were adults at the time of consent. Capacity for
consent was ensured using three measures 1) Schizo-
phrenic patients gave consent only during a “normal”
phase (no psychosis present), 2) Both twins of the twin
pair were present and gave consent at the same time (the
normal twin and their affected sibling), 3) If R.O’Reilly felt
that capacity to consent was compromised, the patients
were not included in our study. They were interviewed
and clinically assessed by a single senior Psychiatrist (R.
O’Reilly) using the SCID-I and SCID-II [23,24]. Past clin-
ical notes were available to aid in diagnosis. Both families
were comprised of identical female twins. The twins from
Family 1 (Figure 1) were Caucasian females aged 43. The
affected member of twin pair 1 was diagnosed with schi-
zoaffective disorder at age 27. The twins were discordant
for 16 years at the time of sample collection. The twins
from Family 2 (Figure 1) were Afro-American females
aged 53. The affected member of twin pair 2 was diag-
nosed with schizophrenia at age 22. The twins were
discordant for 31 years at the time of sample collection.
The twins and their parents (Figure 1) included in this
study contributed whole blood samples for DNA isolation.
Both pairs of monozygotic twins were female twins. DNA
was extracted from whole blood using the 5 Prime Perfect
Pure DNA Blood Kit (Gaithersburg, MD, USA), following
the manufacturer’s protocol. It should be noted that the
Father of Twin Pair 2 was diagnosed with Chronic
Leukemia (CLL) at age 69. The affected patient from
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combination of the medications Seroquel, Effexor and
Topiramate. The affected patient from Family 2 was
treated for schizophrenia symptoms using a combination
of the medications Clozapine, Divalproex and Benztropine.
Zygosity was confirmed by Affymetrix 6.0 microarray and
specifically using the Affymetrix Genotyping Console 4.0
concordance feature [6].
The genomic DNA was processed at ArrayStar Inc
(Rockville, MD, USA); this included the methylated
DNA immunoprecipitation (MeDIP), sample labeling,
and hybridization to the NimbleGen Human DNA Methy-
lation Promoter Plus CpG Island 720k Array. The Nimble-
Gen Human DNA Methylation 3x720k CpG Island Plus
RefSeq Promoter Microarray is a multiplex slide with 3
identical arrays per slide. Each Roche Nimblegen Inc
(Madison, MI, USA) array covers 27,728 annotated CpG
islands as well as 22,532 promoters of the RefSeq genes
derived from the UCSC RefFlat files. Median-centering,
quantile normalization, and linear smoothing was per-
formed by Bioconductor packages Ringo, limma, and
MEDME at ArrayStar. Lastly, in order to compare the two
groups’ differentially enriched regions the average of the
log2-ratio values for each group (i.e. experimental patient
[E] and healthy control [C]) was used to calculate M’ value
(defined by the following equation) for each probe.
M’ ¼ Average log2 MeDIPE=InputEð Þ
− Average log2 MeDIPC=InputCð Þ
The differential enrichment peaks were filtered ac-
cording to the following criteria:
i). At least one of the two groups has a median (log2
MeDIP/Input) > =0.3 and M’> 0.
ii). At least half of probes in a peak may have coefficient
of variability (CV) < = 0.8 in both groups.
Before hybridization to the array, genomic DNA was
sonicated to random fragments in size of about 200–
1000 bp. Immunoprecipitation of methylated DNA was
performed using Biomag™ magnetic beads coupled to a
mouse monoclonal antibody against 5-methylcytidine.
The immunoprecipitated DNA was eluted and purified
by phenol chloroform extraction and ethanol precipita-
tion. The total input and immunoprecipitated DNA were
labeled with Cy3- and Cy5-labeled random 9-mers.
Scanning was performed with the Axon GenePix 4000B
microarray scanner. Raw data was extracted as pair files
by NimbleScan software.
The pair files were analyzed with the tiling workflow in
Partek Genomics Suite® version 6.6 (St. Louis, Missouri,
USA). Nimblegen scan pair files (635 nm and 532 nm) for
each sample were annotated against hg18 and enrichedregions were detected using a two-way ANOVA between
an affected twin and their unaffected co-twin. The
enriched regions settings were set at a minimum p-value
of 0.001 and the number of probes to call a region was set
at a minimum of 4. MAT scores were generated for each
differentially methylated region. Overlapping genes were
then identified as those RefSeq (2014-04-29 version) genes
that were either within the gene or 5000 bp upstream or
3000 downstream of the gene. Differentially methylated
regions (DMRs) in each affected twin were identified in re-
lation to the pattern in the well twin. Also, the presence or
absence of each DMR was assessed as familial or de novo
based on their presence or absence in Mom and/or Dad.
The identified genes with significant changes in DNA
methylation between twins discordant for schizophrenia
(DMRs) were then analyzed using Ingenuity Pathway
Analysis (Ingenuity Systems Inc, CA, USA) towards
identification of networks and canonical pathways over-
represented in the enriched genes. Also, pathway ana-
lysis and gene ontology analysis were conducted using
Partek Pathways (Fishers Exact Test) and Enrichr [25].
Shared genes were annotated with imprinting data from
GeneImprint (http://www.geneimprint.com) and The
Catalogue of Parent of Origin Effects (http://igc.otago.ac.
nz/home.html).
Results
We report the genome-wide analysis of methylation dif-
ferences in two families with monozygotic twins discord-
ant for schizophrenia using the NimbleGen Human
DNA Methylation Promoter Plus CpG Island 720k
Array. The data was analyzed with Partek Genomics
Suite and yielded three main lines of results presented
below:
MZ twins show differences in DNA Methylation profiles
The genome-wide DNA methylation profiles have re-
vealed differentially methylated peaks and regions
(DMRs) between the MZ twin pairs in our study (p ≤
0.001). Further, the availability of parental data has
allowed us to assess each DMR for its presence/absence
in the two parents. The results show that methylation
profiles in twins include both shared and de novo events
(arising from environmental exposures or random
events). We note that in Family 1 as well as in Family 2
(Figure 1), most of the DMRs appear de novo (are not
found in Mom or Dad) as only 25% and 13% of the DMRs,
respectively, were present in either Mom or Dad. The re-
sults have also allowed identification of specific genes that
are differentially methylated between the affected twin and
their identical unaffected twin. Specifically, we note that
138 genes are differentially methylated in the twin pair
from Family 1 (see Additional file 1) and 330 genes are dif-
ferentially methylated in Family 2 (see Additional file 2). A
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specifically the outside track of the Circos diagram repre-
sents DMRs in Family 2, the middle track represents
DMRs in Family 1 and the inside track represents 27 over-
lapping DMRs annotated with gene identity. An overlap
between the DMRs present in the affected member of the
two unrelated families (Figure 3) suggests that most (80-
92%) of the DMRs are twin pair specific. Chromosome 1
(19 and 36 DMRs respectively) and Chromosome 15 (21
and 30 DMRs respectively) show the most DMRs in Fam-
ily 1 as well as in Family 2. Family 2 also has a large num-
ber of DMRs on Chromosome 19 (30 DMRs).
MZ twins discordant for schizophrenia share genomic
regions of differential methylation
Figure 3 shows 27 genes that were differentially methyl-
ated in two affected twins. Of the genes that showed
methylation differences in both sets of twins, 24 were in-
creased in methylation status in the affected twins. TheFigure 2 Differential methylation in two twin pairs in a Circos plot coverin
regions in each affected twin as well as shared regions between both affec
the affected twin and blue represents an increase in methylation in the affect
the affected member of Family 2, the middle track represents differentially me
represents the shared regions found in both unrelated affected twins. Affectelist of genes (Table 1) identified shared common regions
with exact DMR start/end locations in the two patients.
The exception was the PTPRN2 (Entrez Gene: 5799),
TTYH3 (Entrez Gene: 80727) and ZFP41 (Entrez Gene:
286128) regions where the DMRs were found to be
nearby (Table 1). Also, the sequences affected are spe-
cific to the promoter regions as expected.
Interestingly, a subset of common genes identified (5
genes), belong to either the HIST2H cluster on Chromo-
some 1 or the HIST1H region on Chromosome 6 (Table 1).
Further, 17 of the 27 genes belong to either the SNORD115
(Entrez Gene: 692218) or SNORD116 (Entrez Gene:
692236) clusters on chromosome 15. All seventeen of the
SNORD genes identified in two patients are known to be
genomically imprinted and produce ncRNA transcripts
that undergo extensive processing and form many func-
tional classes of non-coding regulatory RNA (Table 1). This
region can be seen in detail in Figure 4 that extends from
the SNRPN gene (Entrez Gene: 6638) to the UBE3A geneg all chromosomes. Circos plot representing differentially methylated
ted twins in our study. Red represents a decrease in methylation in
ed twin. The outside track represents differentially methylated regions in
thylated regions in the affected member of Family 1 and the inside track
d genes are labeled.
Figure 3 Overlap of differentially methylation regions. Venn diagram showing the number of genes differentially methylated in each patient (138 and
330 respectively) as well as the genes enriched in both affected twins in the study (27).
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SNORD116 gene families. Ingenuity Pathway Analysis
(IPA) involving the shared genes has identified Protein
Kinase A Signaling as the most enriched canonical path-
way (p = 3.09E-04). In addition, Granzyme A Signaling
(p = 6.83E-03), G Protein Signaling Mediated by Tubby
(p = 1.24E-02), Serotonin Receptor Signaling (p = 1.72E-
02) and UVB-Induced MAPK Signaling (p = 2.12E-02)
were identified as canonical pathways of interest (Table 2c).
IPA also identified DRD4 (Entrez Gene: 1815), a dopamine
receptor gene, to be the top upstream regulator of the
twenty-seven common genes. Similarly, IPA identified de-
velopmental disorders (p = 4.03E-04-1.21E-03) as a top
disease associated with this gene set while, Cell Signaling
(p = 4.03E-04-3.73E-02), Nucleic Acid Metabolism (p =
4.03E-04-3.73E-02) and gene expression (p = 3.62E-03-
9.63E-03) have been revealed as significant molecular and
cellular functions. Also, Nervous System Development and
Function (p = 1.61E-03-1.61E-03) has been revealed as one
of the top physiological systems related to this gene set.
Further, Infectious Disease, Hereditary Disorders, Embry-
onic Development and Cell Death and Survival were
notable associated network functions related to the differ-
entially methylated gene set in both schizophrenic twins.
When the 27 genes were analyzed using Enrichr [25], ex-
pression in whole brain was identified as the top human
gene atlas finding. Enrichr also identified OMIM disease
classifications related to neurodevelopment to be enriched
in our gene list; these include Asperger’s syndrome (p =
0.039) and mental retardation (p = 0.065).
Unrelated MZ twins discordant for schizophrenia have
differentially methylated networks; some pair specific and
others shared
IPA analysis on the DMRs identified in Family 1 shows
that they are implicated in Developmental Disorders(p = 3.93E-03-3.21E-02), Hereditary Disorders (p = 3.93E-
03-4.58E-02), Skeletal and Muscular Disorders, (p =
3.93E-03-3.21E-02) and Neurological Disease (p = 4.77E-
03-3.54E-02) as these were the top diseases and disorders
associated with the DMR gene set (Table 2). Similarly, in
Family 2, they are implicated in Skeletal and Muscular
Disorders (p = 9.34E-04-4.07E-02) as a top disease and
disorder followed by Cancer (p = 2.09E-04-4.07E-02),
Gastrointestinal Disease (p = 8.86E-04-4.07E-02) and Or-
ganismal Injury and Abnormalities (p = 9.34E-04-3.94E-
02). This analysis also identified a number of interesting
canonical pathways including Human Embryonic Stem
Cell Pluripotency (p = 6.45E-05), Tec Kinase Signaling
(p = 1.51E-04) and IL-4 Signaling (p = 6.49E-03) in
Family 1. In contrast, the canonical pathways of interest
in Family 2 included Hepatic Cholestasis (p = 1.05E-04),
Granzyme A Signaling (p = 1.51E-03) and STAT3 Path-
way (p = 3.31E-03). Other twin specific networks and
functions identified are listed in Tables 2a and b.
This analysis also identified two functional networks
that were affected in both unrelated twin pairs (Figure 5).
They included a cell death and survival network (ratio of
differentially methylated genes to total number of genes
in the network was 12/35 and 9/35, in Family 1 and
Family 2, respectively) (Figure 5a) and a cellular move-
ment and immune cell trafficking network (14/35 and
11/35 genes in Family 1 and 2, respectively) (Figure 5b).
In Family 1, the Cell Death and Survival network identi-
fied IL1B (Entrez Gene: 3553) as the primary hub gene
of the network, while in Family 2, TP53 (Entrez Gene:
7157) was identified as the primary hub gene in this net-
work. Similarly, the cellular movement and immune cell
trafficking networks involves TNF (Entrez Gene: 7124)
and IFNG (Entrez Gene: 3458) as hub genes in Family 1
and IGF1R (Entrez Gene: 3480) and EGFR (Entrez Gene:
1956) as hub genes in Family 2. The results may argue
Table 1 Differentially methylated regions identified in two affected MZD twins belonging to two unrelated families






Found in Family 1
parental
Found in Family 2
parental
HIST2H2AA3 1 148085850 148085870 −3382 Increase 8.45215 12.7557 YES (Both) YES (Mom)
HIST2H2AA4 1 148085850 148085870 −3382 Increase 8.45215 12.7557 YES (Both) YES (Mom)
HIST2H3A 1 148085850 148085870 −4935 Increase 8.45215 12.7557 YES (Both) YES (Mom)
HIST2H3C 1 148085850 148085870 −4935 Increase 8.45215 12.7557 YES (Both) YES (Mom)
HIST1H1C 6 26164302 26164322 357 Increase 6.0215 7.54892 NO NO
PTPRN2 7 F1:157141154 F2:157352628 F1:157141174 F2:157352648 F1:932070 F2:720596 Increase 2.41616 7.11519 NO NO
TTYH3 7 F1:2653547 F2:2664585 F1:2653567 F2:2664605 F1:15418 F2:26456 F1:Increase F2:Decrease 2.47725 −2.82779 NO NO
ZFP41 8 F1:144403919 F2:144409425 F1:144403939 F2:144409445 F1:3446 F2: 8952 Increase 2.05379 15.1625 NO NO
SNORD115-10 15 22983806 22983826 30 Increase 7.8983 7.49051 YES (Both) YES (Both)
SNORD115-11 15 22983806 22983826 −1828 Increase 7.8983 7.49051 YES (Both) YES (Both)
SNORD115-12 15 22983806 22983826 1935 Increase 7.8983 7.49051 YES (Both) YES (Both)
SNORD115-29 15 22983806 22983826 −1828 Increase 7.8983 7.49051 YES (Both) YES (Both)
SNORD115-33 15 23030052 23030072 2974 Increase 7.8983 7.49051 YES (Both) YES (Both)
SNORD115-34 15 23030052 23030072 1425 Increase 7.8983 7.49051 YES (Both) YES (Both)
SNORD115-35 15 23030052 23030072 −415 Increase 7.8983 7.49051 YES (Both) YES (Both)
SNORD115-36 15 22983806 22983826 −1828 Increase 7.8983 7.49051 YES (Both) YES (Both)
SNORD115-37 15 23030052 23030072 −4154 Increase 7.8983 7.49051 YES (Both) YES (Both)
SNORD115-43 15 22983806 22983826 −1828 Increase 7.8983 7.49051 YES (Both) YES (Both)
SNORD115-5 15 22983806 22983826 1932 Increase 7.8983 7.49051 YES (Both) YES (Both)
SNORD115-9 15 22983806 22983826 1935 Increase 7.8983 7.49051 YES (Both) YES (Both)
SNORD116-10 15 22868070 22868090 −2263 Increase 7.8983 7.49051 YES (Both) YES (Both)
SNORD116-11 15 22868070 22868090 −4078 Increase 7.8983 7.49051 YES (Both) YES (Both)
SNORD116-3 15 22868070 22868090 −1256 Increase 7.8983 7.49051 YES (Both) YES (Both)
SNORD116-8 15 22868070 22868090 1399 Increase 7.8983 7.49051 YES (Both) YES (Both)
SNORD116-9 15 22868070 22868090 −1256 Increase 7.8983 7.49051 YES (Both) YES (Both)
GNAS 20 56879799 56879819 18368 F1:Decrease F2:Increase −10.7502 17.2187 YES (Both) YES (Both)
XIST X 72974756 72974776 14538 F1:Decrease F2:Increase −7.36623 12.1903 YES (Both) NO














Figure 4 Manhattan plot representing methylation in the 15q11.2-15q12 region in the twin pairs of Family 1. This region spans from SNRPN to
UBE3A and encompasses members of the SNORD115 and SNORD116 gene families (top). A red dot indicates a decrease in methylation in the
affected twin. A blue dot indicates an increase in methylation in the affected twin (Family 1). This region contains a complex regulatory ncRNA
involved in imprinting control and neurodevelopment.
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the etiology of schizophrenia and related disorders.
Discussion
The results included in this report support that monozy-
gotic twins differ in DNA methylation. This difference is
genome-wide and includes a relatively large number of
presumed de novo events. The results suggest that de
novo methylation changes are common during develop-
ment and aging in the two pairs studied. The results
therefore are specific to the two patients and will not
necessarily cover the whole spectrum of the disease.
Taken together, the results call for further assessment of
epigenetic profiles in an increased number of rare dis-
cordant twin pairs, as the analysis included in this reportis based on two female pairs only. The DMRs may repre-
sent random events over the lifetime or arise from
shared environmental conditions [20,21,26]. Further, al-
though the two MZD pairs for schizophrenia are unre-
lated, they share differences in DNA methylation in 27
genes and genomic locations. Interestingly, many of
these shared differences belong to the histone coding
gene family, which has already been implicated in the
causation of schizophrenia [12,21,27]. Also, the differen-
tially methylated genes affect two networks that are
compatible with the development of this neurodevelop-
mental disease. Finally, the genes identified have the po-
tential to explain the discordance of the two twin pairs
for schizophrenia. Of special interest to this discussion
are HIST genes primarily located on chromosome 1 and
Table 2 Ingenuity pathway analysis (IPA) results a) Family 1
b) Family 2 c) Subset of 27 genes found in both affected
twins
a. Family 1
Biological function P-value Genes
Diseases and disorders
Developmental Disorder 3.93E-03 - 3.21E-02 10
Hereditary Disorder 3.93E-03 - 4.58E-02 19
Skeletal and Muscular Disorders 3.93E-03 - 3.21E-02 5
Neurological Disease 4.77E-03 - 3.54E-02 13
Molecular and cellular functions
Carbohydrate Metabolism 7.88E-04 - 2.06E-02 3
Lipid Metabolism 7.88E-04 - 2.06E-02 3
Small Molecule Biochemistry 7.88E-04 - 4.58E-02 7
Gene Expression 2.63E-03 - 4.58E-02 18
Cell Death and Survival 5.20E-03 - 3.16E-02 13
Canonical pathways
Human Embryonic Stem Cell
Pluripotency
6.45E-05 6/149 (0.04)
Tec Kinase Signaling 1.51E-04 6/175 (0.034)
Sphingosine-1-phosphate Signaling 2.42E-03 4/115 (0.035)
Renal Cell Carcinoma Signaling 5.55E-03 3/71 (0.042)
IL-4 Signaling 6.49E-03 3/75 (0.04)
Physiological system development and function
Cardiovascular System Development
and Function
5.20E-03 - 3.58E-02 1
Hair and Skin Development and
Function
5.20E-03 - 4.58E-02 2
Hematological System Development
and Function
5.20E-03 - 4.13E-02 7
Immune Cell Trafficking 5.20E-03 - 4.13E-02 3
Associated network functions
Cell Death and Survival, Cellular Movement, Cellular
Function and Maintenance
Score = 19
Cellular Movement, Immune Cell Trafficking,
Hematological System Development and Function
Score = 17
Hereditary Disorder, Skeletal and Muscular Disorders,
Developmental Disorder
Score = 9
Connective Tissue Disorders, Dermatological Diseases and
Conditions, Hematological System Development and
Function
Score = 2
Organ Morphology, Reproductive System Development
and Function, Cellular Function and Maintenance
Score = 2
b. Family 2
Cancer 2.09E-04 - 4.07E-02 204
Gastrointestinal Disease 8.86E-04 - 4.07E-02 29
Organismal Injury and Abnormalities 9.34E-04 - 3.94E-02 46
Skeletal and Muscular Disorders 9.34E-04 - 4.07E-02 36
Molecular and cellular functions
Lipid Metabolism 1.88E-04 - 4.07E-02 7
Table 2 Ingenuity pathway analysis (IPA) results a) Family 1
b) Family 2 c) Subset of 27 genes found in both affected
twins (Continued)
Molecular Transport 1.88E-04 - 4.07E-02 9
Small Molecule Biochemistry 1.88E-04 - 4.07E-02 19
Cellular Growth and Proliferation 3.06E-04 - 4.07E-02 21
Cell Morphology 5.59E-04 - 3.63E-02 10
Canonical pathways
Hepatic Cholestasis 1.05E-04 9/141(0.064)
Granzyme A Signaling 1.51E-03 3/17 (0.176)
Ovarian Cancer Signaling 2.24E-03 7/138 (0.051)
STAT3 Pathway 3.31E-03 5/74 (0.068)
Colorectal Cancer Metastasis Signaling 4.9E-03 9/244 (0.037)
Physiological system development and function
Cardiovascular System Development
and Function
1.88E-04 - 4.07E-02 10
Digestive System Development and
Function
1.88E-04 - 1.88E-04 2
Embryonic Development 1.88E-04 - 4.07E-02 14
Organ Development 1.88E-04 - 4.07E-02 6
Associated network functions
Cell Death and Survival, Cellular Development, Connective
Tissue Development and Function
Score = 39
Cellular Movement, Immune Cell Trafficking,
Hematological System Development and Function
Score = 12
Cancer, Organismal Injury and Abnormalities, Reproductive
System Disease
Score = 11
Cell Death and Survival, Cellular Movement, Renal
Necrosis/Cell Death
Score = 11
Cell Morphology, Cellular Function and Maintenance, Cell
Cycle
Score = 9
c. Shared DMRs between both families
Cancer 4.03E-04 - 4.50E-02 5
Connective Tissue Disorders 4.03E-04 - 8.05E-04 1
Developmental Disorder 4.03E-04 - 1.21E-03 1
Endocrine System Disorders 4.03E-04 - 4.50E-02 2
Molecular and cellular functions
Cell Signaling 4.03E-04 - 3.73E-02 1
Nucleic Acid Metabolism 4.03E-04 - 3.73E-02 1
Small Molecule Biochemistry 4.03E-04 - 3.73E-02 1
Gene Expression 3.62E-03 - 9.63E-03 1
Cellular Movement 6.43E-03 - 6.43E-03 1
Canonical pathways
Protein Kinase A Signaling 3.09E-04 3/368 (0.008)
Granzyme A Signaling 6.83E-03 1/17 (0.059)
G Protein Signaling Mediated by
Tubby
1.24E-02 1/31 (0.032)
Serotonin Receptor Signaling 1.72E-02 1/43 (0.023)
UVB-Induced MAPK Signaling 2.12E-02 1/53 (0.019)
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Table 2 Ingenuity pathway analysis (IPA) results a) Family 1
b) Family 2 c) Subset of 27 genes found in both affected
twins (Continued)
Physiological system development and function
Nervous System Development and
Function
1.61E-03 - 1.61E-03 1
Hematological System Development
and Function
6.43E-03 - 2.47E-02 1
Immune Cell Trafficking 6.43E-03 - 6.43E-03 1
Behavior 2.04E-02 - 2.04E-02 1
Associated network functions
Infectious Disease, Cancer, Gastrointestinal Disease Score = 3
Tissue Morphology, Organismal Survival, Gene Expression Score = 3
Hereditary Disorder, Gene Expression, Embryonic
Development
Score = 3
DNA Replication, Recombination, and Repair, Gene
Expression, Cancer
Score = 3
Cell Death and Survival, Cellular Function and
Maintenance, Connective Tissue Development and
Function
Score = 3
Castellani et al. BMC Medical Genomics  (2015) 8:17 Page 9 of 12SNORD115 and SNORD116 genes located on chromo-
some 15. In addition, the two patients share identified
networks affecting cell death and immune cell traffick-
ing, which are elaborated on below.
It is noteworthy that our study identified 5 HIST genes
as genes of interest in the discordance for schizophrenia.
A Histone gene cluster on Chromosome 6 has been pre-
viously implicated in a meta-analysis of schizophrenia
associated loci in individuals of European ancestry [28].
The implicated region itself, 6p22.1, was also found to
be associated with schizophrenia [28]. In addition, his-
tone methylation has been found in olfactory cells impli-
cating oxidative stress in schizophrenia [29]. Lastly,
postmortem brain tissue from schizophrenia patients
has been found to have higher levels of histone deacety-
lase, HDAC1, and the level of HDAC1 has been shown
to be inversely correlated with GAD67 (Entrez Gene:
2571) protein expression, which tends to be decreased in
schizophrenia patients [30,31] and argues that histones
may play a role in this complex disease.
The SNPRN-UBE3A locus, which encompasses the
SNORD115 and SNORD116 gene families, is a complex
non-coding RNA region that spans 15q11-q13 [32].
Noncoding RNAs, including miRNAs, are known to
fine-tune gene expression through transcriptional and
post-transcriptional regulations including RNA stability
and protein translation [33]. In addition to serving as an
antisense RNA for UBE3A, the polycistronic transcript is
also a host that undergoes extensive processing, includ-
ing the production of a number of small nucleolar RNA
species (snoRNAs). The HBII-52 snoRNAs (also known as
the SNORD115 family) regulate the alternative splicing ofthe 5HTR2C serotonin receptor and result in an increased
serotonin response in neurons [34]. SNORD115 is further
processed into processed snoRNAs (psnoRNAs) that go
on to regulate alternative splicing in a number of other
transcripts, including epigenomic modifiers [35]. How-
ever, a conflicting report emerged in 2012 that showed
evidence against psnoRNAs, indicating that SNORD115
and SNORD116 may generate genuine snoRNAs [36].
A novel ncRNA species, LncRNAs with snoRNA ends,
also originates from this loci. They are functionally dis-
tinct from snoRNAs and lncRNAs and are associated
with the FOX family of splicing regulators that alter the
alternative splicing of a number of other genes. In
addition to psnoRNAs, snoRNAs, and lnc-snoRNAs,
the snoRNAs are even further processed into snoRNA-
derived RNAs (sdRNAs). These sdRNAs are proposed
to come in two variations: some resembling miRNAs
that associate with argonaute proteins to regulate
translation and another longer type that form com-
plexes to influence gene expression [37]. Further inves-
tigation into the locus has shown that it produces even
more ncRNA products, with the introns forming the
snoRNA derivatives and the exons forming two distinct
but overlapping neuronal lncRNA clouds from the
SNORD 115 and SNORD116 regions that are involved
in modulating circadian rhythm and energy expend-
iture [38,39]. The lncRNAs are functionally distinct
from the earlier identified ncRNA species and are also
primarily expressed in developing neurons.
Interestingly, the lncRNA from the SNPRN-UBE3A re-
gion has been suggested to regulate another imprinted
locus, the DLK1-DIO3 region, which is the only other
known imprinted cluster of ncRNA that produces lncRNA,
miRNA, and snoRNA. It is also involved in neurodevelop-
ment and suggests that imprinted ncRNAs are capable of
‘genomic cross-talk’ [40,41]. Interestingly, while imprinting
disorders are known to originate from these loci, a
highly resolved and restricted deletion in the SNORD116
region was identified as the minimal mutation to cause
Prader-Willi Syndrome [42]. Also, DRD4, a top upstream
regulator identified in the shared DMR gene set, has been
previously implicated in schizophrenia, and is thought to
be the target of many antipsychotics [43].
The identified networks across unrelated twins share
common functions supporting the hypothesis that a dif-
ferent set of patient specific gene insults may lead to dis-
ease symptoms. There has been a long held linkage
between schizophrenia and immune cell function. This
theory gained further support as novel functions of im-
mune molecules in the brain and cross-talk between the
immune system and the central nervous system [44]. In
addition, a number of studies have shown up-regulation
of immune-inflammatory genes in the CNS [44-46] as
well as immune system gene modulation of synaptic
Figure 5 Common networks identified in both families. a. Two cell death and survival networks independently identified in each affected twin in
our study. Ingenuity Pathway Analysis (IPA) was used to identify the networks in both affected twins in our study. Shading represents genes in
our study that are differentially methylated in the network. b. Two cellular movement and immune cell trafficking networks independently identified in
each affected twin in our study. Ingenuity Pathway Analysis (IPA) was used to identify the networks in both affected twins in our study. Shading
represents genes in our study that are differentially methylated in the network.
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trafficking networks identified in Family 1, two genes (TNF
and IFNG) immerged as hub genes. The tumor necrosis
factor (TNFα) had been associated with schizophrenia and
also it was reported that immune dysregulation could have
a genetic component in schizophrenia patients [48]. Also,
a single nucleotide polymorphism in the interferon gamma
gene (IFNG) had been associated with paranoid schizo-
phrenia in males [49], however, the role of the gene in the
pathophysiology of the disease remains to be elucidated.
Similarly, the other hub gene of cellular movement and
immune cell trafficking network, EGFR, identified in Fam-
ily 2 have also been associated with schizophrenia [50].The primary hub gene in the Cell Death and Survival
network, IL1B, which is differentially methylated in Family
1, has an important role in the development of the central
nervous system. Also, it is reported to be associated with
schizophrenia [51]. Similarly, the human p53 tumor sup-
pressor gene (TP53), which is identified as a primary hub
gene in the cell death and survival network of Family 2 in
this study, plays a role in neurodevelopment and was pre-
viously associated with schizophrenia [52].
Finally, the question of the effect of the observed DNA
methylation on disease must be interpreted with caution.
We may add that most schizophrenia patients are ex-
posed to antipsychotic drugs in North America. Our
Castellani et al. BMC Medical Genomics  (2015) 8:17 Page 11 of 12patients were under treatment with medications, though
not consistently. We note that such drugs and cellular
heterogeneity of the studied samples [53] may also affect
DNA methylation [54] as confounding factors. Further,
although practical, we recognize the use of blood to
make inferences regarding a brain-based disorder is not
without caution and recommend that this discovery
study be complemented by population studies of larger
sample size on this disease as well as confirmation of the
findings using alternative technologies. However, in its
current state, it is not possible to eliminate these and
other confounding factors that may affect our results at
this time. The specific observations on genes and path-
ways relevant to the disease however, lend support to
the complexity of this neurodevelopmental disease and
its aetiology.Conclusions
We report genome-wide methylation differences be-
tween monozygotic twins discordant for schizophrenia.
A number of genes and networks identified are twin
pair-specific, while others are shared between unrelated
patients. Most patient specific genes and gene networks
affected have been previously implicated in schizophrenia.
Specifically, the results identify three sets of gene clus-
ters, HIST (Chromosome 1), SNORD115 and SNORD116
(Chromosome 15), which are differentially methylated in
the twins with schizophrenia as compared to their un-
affected counterpart. We also report common networks
identified independently in the two patients that relate to
cell death/survival and immune cell trafficking networks
disrupted in schizophrenia. The results on monozygotic
discordant twins argue for a network based rather than
gene focused approach in the understanding of schizo-
phrenia and related disorders.Availability of supporting data
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